77232-38-3

Usage

Uses

Used in Pharmaceutical Industry:
4-(PYRIMIDIN-2-YL)BENZALDEHYDE is used as an intermediate for the synthesis of anti-cancer drugs, anti-inflammatory agents, and other therapeutic compounds due to its diverse pharmacological properties.
Used in Organic Synthesis:
4-(PYRIMIDIN-2-YL)BENZALDEHYDE is used as a reagent and building block in organic synthesis, making it an important chemical in the field of medicinal and pharmaceutical chemistry.

InChI:InChI=1/C11H8N2O/c14-8-9-2-4-10(5-3-9)11-12-6-1-7-13-11/h1-8H

Upstream product

• 77232-37-2 2-(4-Bromomethyl-phenyl)-pyrimidine 
• 87199-17-5 4-formylphenylboronic acid, 
• 6326-27-8 p-methylbenzamidine hydrochloride 
• 21139-61-7 2-(4-methylphenyl)-4,6-dichloropyrimidine 
• 77232-12-3 2-(4-methylphenyl)-4,6-dihydroxypyrimidine 
• 77232-13-4 2-p-tolyl-pyrimidine 
• 4595-60-2 2-bromopyrimidine 

Downstream Products

• 199678-12-1 4-(pyrimidine-2-yl)benzoic acid 
• 503176-25-8 (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenal 
• 545424-74-6 (2Z)-2-Fluoro-3-[4-(2-pyrimidinyl)phenyl]-2-propenoic Acid Ethyl Ester 

Relevant academic research and scientific papers

BROAD SPECTRUM ANTIVIRAL COMPOSITIONS AND METHODS

Novel thiazole- and isoquinoline- containing compounds are presented that are useful for treating and/or preventing broad-spectrum viral infections. Methods of treating and/or preventing broad-specturm viral infections are also presented. These compounds have shown inhibitio of HCMV, influenza viruses, Zika virus, BK Virus and RSV replication in cell-based assays.

Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: Potent inhibitors of R5 HIV-1 replication

The redesign of the previously reported thiophene-3-yl-methyl urea series, as a result of potential cardiotoxicity, was successfully accomplished, resulting in the identification of a novel potent series of CCR5 antagonists containing the imidazolidinylpiperidinyl scaffold. The main redesign criteria were to reduce the number of rotatable bonds and to maintain an acceptable lipophilicity to mitigate hERG inhibition. The structure-activity relationship (SAR) that was developed was used to identify compounds with the best pharmacological profile to inhibit HIV-1. As a result, five advanced compounds, 6d, 6e, 6i, 6h, and 6k, were further evaluated for receptor selectivity, antiviral activity against CCR5 using (R5) HIV-1 clinical isolates, and in vitro and in vivo safety. On the basis of these results, 6d and 6h were selected for further development.

Methods of treatment using an EP2 selective receptor agonist

The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP2 selective receptor agonist.

Biarylcarboxybenzamide derivatives as potent vanilloid receptor (VR1) antagonistic ligands

Seventeen biarylcarboxybenzamide derivatives were prepared for the study of their agonistic/antagonistic activities to the vanilloid receptor (VR1) in rat DRG neurons. The replacement of the piperazine moiety of the lead compound 1 with phenyl ring showed quite enhanced antagonistic activity. Among the prepared derivatives, N-(4-tert-butylphenyl)-4-pyridine-2-yl-benzamide (2, IC 50 = 31 nM) and N-(4-tert-butylphenyl)-4-(3-methylpyridine-2-yl) benzamide (3g, IC50 = 31 nM), showed 5-fold higher antagonistic activity than 1 in 45Ca2+-influx assay.

THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE

The invention relates to thienopyrimidinediones of formula (1) wherein R1 and R2 each independently represent a C1-6akyl, C3-6alkyl, C3-6alkenyl, C3-5cycloalkylC1-3alkyl or Csub

Method for treating glaucoma

Methods of using prostaglandin agonists for the reduction of intraocular pressure, and accordingly glaucoma.

Prostaglandin agonists and their use to treat bone disorders

This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

Prevention of loss and restoration of bone mass by certain prostaglandin agonists

Prostaglandin agonists of formula (I), in which, for example, A is a sulphonyl or acyl group, B is N or CH, M contains a ring and K and Q are linking groups, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits useful for the treatment of bone disorders including osteoporosis. STR1

Ueber die Herstellung von Styryl- und Stylbenyl-Derivaten des Pyrimidins

2- and 4-(p-Tolyl)-substituted pyrimidines react with anils of hetero-aromatic aldehydes in the presence of dimethylformamide and potassium hydroxide or potassium t-butoxide to yield the corresponding 2- and 4-pyrimidines or